{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-078135","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.375999+00:00","generated_at":"2026-05-17T13:09:24.592646+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"VYNE Q2 net loss $5.8M; cash runway extended to H1 2027; two directors resign","bullets":["Cash, equivalents and marketable securities $39.6M as of Jun 30, expected to fund ops into first half of 2027.","Net loss $5.8M ($0.13 per share) vs $9.4M ($0.22) in Q2 2024; revenue $0.1M from Finacea royalty.","Directors Christine Borowski and Anthony Bruno resigned effective Aug 11 and 13, 2025; no dispute with company.","Repibresib Phase 2b vitiligo trial missed primary endpoint; company seeking partner for program.","FDA lifted clinical hold on VYN202 Phase 1b for female subjects; partial hold remains for males pending new toxicology study."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-078135","json":"https://secwatch.observer/filing/0001104659-25-078135.json","markdown":"https://secwatch.observer/filing/0001104659-25-078135.md","text":"https://secwatch.observer/filing/0001104659-25-078135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465925078135/0001104659-25-078135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465925078135/tm2523400d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:09:24.592646+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}